We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 50

Indian Supreme Court assesses care or cure properties of product in tariff dispute

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • August 29 2013

The Indian Supreme Court has affirmed lower tribunal rulings that Moisturex is a medicament used for its curative properties and, as such, is

India’s biotechnology regulatory bill faces opposition

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • November 17 2011

According to a news source, the proposed Biotechnology Regulatory Authority of India Bill, 2011, was withdrawn from the Monsoon Session of Parliament after congressional members and others objected to placing the new regulatory agency under the authority of the Ministry of Science & Technology

India biotech sector set to reach $10 billion by 2015

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • May 19 2011

According to a news source, India's biotechnology sector is expected to reach $10 billion in revenue by 2015

India to consider ban on importing animal-tested cosmetics

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • January 9 2014

Following the June 2013 decision to prohibit the testing of domestically produced cosmetics and their ingredients on animals (details about which

House Subcommittee addresses policies blocking U.S. exports to India

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • March 21 2013

The House Ways and Means Trade Subcommittee recently held a hearing on U.S.-India trade relations during which industry groups reportedly called on

Indian Supreme Court rules Novartis cancer drug change not patentable

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also

Indian officials to scrutinize pharmaceutical M&As

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • October 20 2011

Indian ministry officials have apparently decided that foreign companies may continue to invest in new pharmaceutical industry projects but that foreign proposals for mergers and acquisitions in this sector will have to undergo enhanced scrutiny

India’s guidance for biosimilar drugs draws cautious industry welcome

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • September 20 2012

According to a news source, industry has given India’s new guidelines for biosimilar drugs, launched August 15, 2012, a “cautious welcome.”

State body opposes India drugs and cosmetics bill, 2013

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • October 31 2013

According to news sources, the All India Drug Control Officers' Confederation (AIDCOC) has raised objections to proposed amendments to India's Drug

India holds out among countries requiring transparency in industry payments

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • June 20 2013

According to a news source, while many countries have instituted disclosure obligations on health-care companies, often pharmaceutical and